Keywords: six, month, pfs, ph, melanoma, study, roche

Six month PFS in Ph I melanoma study of Roche's BRAF drug

Article | 01 June 2009

Print This

Swiss drug major Roche and US partner Plexxikon reported strong interim results from a Phase I study of PLX4032 (R7204) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in